Sponsors List
We thank the following sponsors for their support to PKU Bio-Net Symposium 2016：
Titled Sponsors
Clindata Insight is a biometrics consulting firm based in the San Francisco Bay Area specializing in biostatistics, statistical programming, CDISC implementation, big data for life science and talent solutions. We support biopharma, medical devices and molecular diagnostic companies in Phase I to Phase III clinical trials and deliver actionable insights from their data to enable evidence-based business decisions. We have seasoned consultants with many years of direct new drug submission experience with FDA, EMA and PMDA. Our therapeutic area encompasses oncology, HIV, liver disease, metabolic disease, ophthalmology, inflammation and dermatology.
Originally from Peking University, Beijing Institute of Collaborative Innovation (www.bici.org) is an open and conglomerate system for collaborative innovation founded under the strong support of the city of Beijing by integrating 14 top universities, and more than 100 industry-leading companies.
Focusing on creating an innovation system, BICI takes an open and collective approach to pursuing a strategy that provides technical support, funding, and other resources to ensure the successful commercialization of early-stage technologies in Life Sciences and other four areas.
Premier Sponsors
Eureka Therapeutics is focused on developing novel T cell immunotherapies for the treatment of solid tumors. Our unique platform is powered by TCR-like antibodies which recognize previously inaccessible cancer antigens specific for solid tumors.In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first to design and demonstrate the efficacy of a human antibody targeting an intracellular cancer antigen (WT-1) for cancer immunotherapy. Eureka’s first clinical study testing our lead liver cancer program is planned to launch in 2016.
Vivo Capital is a healthcare focused investment firm formed in 1996 with over $1.7 billion under management. Vivo Capital is currently making investments from its $750M eighth fund into promising private and public healthcare companies in the U.S. and greater China. Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China.
Basic Sponsors
